Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HER2-CAR-T for Advanced HER2 Positive Breast Cancer
NCT02547961Phase 2Withdrawn
- Sponsor
- Fuda Cancer Hospital
- Start
- Sep 2015
- Primary completion
- Aug 2016
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 2, open-label trial of HER2-CAR-T in breast cancer (2 arms), sponsored by Fuda Cancer Hospital. Primary endpoint: Number of participants with Adverse events at 24 weeks. Planned start Sep 2015; status: withdrawn.
02
Drugs
HER2-CAR-T
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT02547961.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02547961.